[
    [
        {
            "time": "2023-10-15",
            "original_text": "Senate Finance Committee launches probe into AbbVie's tax practices",
            "features": {
                "keywords": [
                    "Senate",
                    "Finance",
                    "Committee",
                    "probe",
                    "AbbVie",
                    "tax",
                    "practices"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "Senate Finance Committee launches probe into AbbVie's tax practices",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rinvoq",
                    "Encouraging",
                    "Long",
                    "Term",
                    "Safety",
                    "Efficacy",
                    "Rheumatoid",
                    "Arthritis",
                    "Psoriatic",
                    "Arthritis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's Rinvoq Shows Encouraging Long Term Safety, Efficacy In Rheumatoid Arthritis, Psoriatic Arthritis Patients",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Goldman",
                    "Sachs",
                    "Annual",
                    "Global",
                    "Healthcare",
                    "Conference"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year",
            "features": {
                "keywords": [
                    "Phase",
                    "3",
                    "Maintenance",
                    "Results",
                    "Patients",
                    "Crohn's",
                    "Disease",
                    "Risankizumab",
                    "SKYRIZI®",
                    "Endoscopic",
                    "Response",
                    "Clinical",
                    "Remission",
                    "One",
                    "Year"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Present",
                    "Analysis",
                    "Evaluating",
                    "Continuous",
                    "RINVOQ®",
                    "upadacitinib",
                    "Treatment",
                    "Psoriatic",
                    "Arthritis",
                    "EULAR",
                    "2021",
                    "Virtual",
                    "Congress"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie Faces U.S. Senate Pressure Over Tax Payments",
            "features": {
                "keywords": [
                    "AbbVie",
                    "U.S.",
                    "Senate",
                    "Pressure",
                    "Tax",
                    "Payments"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false"
            },
            "scores": {
                "News_content": "AbbVie Faces U.S. Senate Pressure Over Tax Payments",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress",
            "features": {
                "keywords": [
                    "Long-Term",
                    "Efficacy",
                    "Safety",
                    "Analyses",
                    "Evaluating",
                    "RINVOQ®",
                    "upadacitinib",
                    "Patients",
                    "Rheumatoid",
                    "Arthritis",
                    "EULAR",
                    "2021",
                    "Virtual",
                    "Congress"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "15 Most Valuable Pharmaceutical Companies In The World",
            "features": {
                "keywords": [
                    "15",
                    "Most",
                    "Valuable",
                    "Pharmaceutical",
                    "Companies",
                    "World"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "15 Most Valuable Pharmaceutical Companies In The World",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]